All potential acute ischemic stroke patients meeting criteria for the use of IV tPA should be offered treatment. The facts are clear, and all that remains is further provider and patient education.

Eligibility criteria for IV thrombolysis therapy must be met before administration of a thrombolytic drug. Criteria for tPA are shown in Figure 5 (Bader & Littlejohns, 2004; Kongable, 1997).

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...